Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1864-1870

  Yu, Evan Y ^a   Kuo, Kevin F ^a   Gulati, Roman ^b   Chen, Shu ^b   Gambol, Teresa E ^a   Hall, Suzanne P ^a   Jiang, Peter Y ^c   Pitzel, Peggy ^a   Higano, Celestia S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Providence Regional Cancer Partnership   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYNAMICS; FRACTURE; HIP; HUMAN; IMAGE ANALYSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SPINE RADIOGRAPHY; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; BONE DISEASES, METABOLIC; DRUG ADMINISTRATION SCHEDULE; FLUTAMIDE; FRACTURES, BONE; HUMANS; LEUPROLIDE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, HORMONE-DEPENDENT; OSTEOPOROSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84863994901     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.3745     Document Type: Article

References (31)

1. Heidenreich A, Aus G, Bolla M, et al: EAU guidelines on prostate cancer. Eur Urol 53:68-80, 2008 (Pubitemid 350166735)
2. Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25:1596-1605, 2007 (Pubitemid 46733088)
3. Messing EM, Manola J, Yao J, et al: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479, 2006 (Pubitemid 43779173)
4. Shahinian VB, Kuo YF, Freeman JL, et al: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615-1624, 2005 (Pubitemid 40490022)
5. Bolla M: Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol 35:23-25; discussion 26, 1999 (suppl 1)
6. Haseen F, Murray LJ, Cardwell CR, et al: The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. J Cancer Surviv 4:128-139, 2010
7. Schwandt A, Garcia JA: Complications of androgen deprivation therapy in prostate cancer. Curr Opin Urol 19:322-326, 2009
8. Smith MR: Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep 9:197-202, 2008
9. Morote J, Morin JP, Orsola A, et al: Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500-504, 2007 (Pubitemid 46428384)
10. Shahinian VB, Kuo YF, Freeman JL, et al: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164, 2005 (Pubitemid 40096612)
11. Smith MR, Boyce SP, Moyneur E, et al: Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175:136-139; discussion 139, 2006
12. Smith MR, Lee WC, Brandman J, et al: Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23: 7897-7903, 2005 (Pubitemid 46657388)
13. Greenspan SL, Coates P, Sereika SM, et al: Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410-6417, 2005 (Pubitemid 41759293)
14. Crook JM, O'Callaghan CJ, Ding K, et al: A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR. 7/SWOG JPR. 7/CTSU JPR. 7/UK Intercontinental Trial CRUKE/01/013). J Clin Oncol 29, 2011 (suppl; abstr 4514)
15. de Leval J, Boca P, Yousef E, et al: Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormonenaive prostate cancer: Results of a prospective randomized multicenter trial. Clin Prostate Cancer 1:163-171, 2002 (Pubitemid 37012397)
16. Bruchovsky N, Klotz L, Crook J, et al: Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer 6:46-52, 2008 (Pubitemid 351656244)
17. Sato N, Akakura K, Isaka S, et al: Intermittent androgen suppression for locally advanced and metastatic prostate cancer: Preliminary report of a prospective multicenter study. Urology 64:341-345, 2004 (Pubitemid 39092467)
18. Spry NA, Kristjanson L, Hooton B, et al: Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 42:1083-1092, 2006 (Pubitemid 44275330)
19. Yu EY, Gulati R, Telesca D, et al: Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 28:2668-2673, 2010
20. Hui SL, Gao S, Zhou XH, et al: Universal standardization of bone density measurements: A method with optimal properties for calibration among several instruments. J Bone Miner Res 12: 1463-1470, 1997 (Pubitemid 27375390)
21. Lu Y, Fuerst T, Hui S, et al: Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int 12:438-444, 2001 (Pubitemid 32607085)
22. Hadfield J: MCMC Methods for multi-response generalized linear mixed models: The MCMCglmm R package. J Stat Softw 33:1-22, 2010
23. Spry NA, Galvão DA, Davies R, et al: Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: Results of a 33-month observational study. BJU Int 104:806-812, 2009
24. Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259, 1996 (Pubitemid 26147662)
25. Smith MR, Egerdie B, Hernandez Toriz N, et al: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745-755, 2009
26. Wadhwa VK, Weston R, Mistry R, et al: Longterm changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 104:800-805, 2009
27. Greenspan SL, Nelson JB, Trump DL, et al: Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial. Ann Intern Med 146:416-424, 2007 (Pubitemid 351650576)
28. Planas J, Trilla E, Raventós C, et al: Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 104:1637-1640, 2009
29. Smith MR, McGovern FJ, Zietman AL, et al: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948-955, 2001
30. Israeli RS, Rosenberg SJ, Saltzstein DR, et al: The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 5:271-277, 2007 (Pubitemid 46867363)
31. Michaelson MD, Kaufman DS, Lee H, et al: Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038-1042, 2007 (Pubitemid 46596753)